Drug Trial News

RSS

Results from Phase 0/1 trial of ribociclib plus everolimus in patients with high-grade glioma announced

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).

13 Sep 2021

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

A recent report published in the journal Cell Discovery has described the immunogenicity and protective efficacy of a novel coronavirus disease 2019 (COVID-19) subunit vaccine candidate. The vaccine induces robust immune responses in rodents and non-human primates and protects the animals against severe disease.

12 Sep 2021

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria, according to research presented today in OA13: Topics in Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer.

12 Sep 2021

High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia

A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a highly aggressive cancer.

12 Sep 2021

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases.

12 Sep 2021

New Columbia-Pfizer Clinical Trials Diversity Initiative aims to reduce health disparities

Columbia University Irving Medical Center, its Herbert Irving Comprehensive Cancer Center, and Pfizer Inc. have established the Columbia-Pfizer Clinical Trials Diversity Initiative, with the aim of reducing health disparities by increasing the participation of underrepresented minorities in clinical trials and enhancing the diversity of clinical researchers.

9 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

HIV vaccine candidate trialed in Sub-Saharan Africa falls short

An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organizers say.

4 Sep 2021

Trial tests effectiveness of two prospective stroke therapies over standard of care

Another goal of the study is to screen all participants for a mutation known to prevent clopidogrel, a prodrug, from being fully metabolized into its active form.

2 Sep 2021

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

1 Sep 2021

UniSA researchers are putting cancer patients at the heart of clinical trials

From bench to bedside, the journey towards new cancer therapies is full of challenges. Clinical trials – where new treatments are tested on people – are vital, but with fewer than five per cent of cancer patients participating worldwide, it’s a long road to travel.

1 Sep 2021

Investigational vaccine does not provide sufficient protection against HIV infection

An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries.

31 Aug 2021

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

$Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction$

Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a distinctly positive effect on prognosis. In patients affected by this type of heart failure, the drug – empagliflozin – reduces the risk of hospitalization or cardiovascular death by 21 percent. The results of this research have been published in the New England Journal of Medicine.

28 Aug 2021

$Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction$

Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.

27 Aug 2021

NIH begins clinical trial to assess extra COVID-19 vaccine dose in people with autoimmune disease

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen.

27 Aug 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.

27 Aug 2021

Previous
1
...
44
45
46
47
48
49
50
...
1143
Next

Drug Trial News

Results from Phase 0/1 trial of ribociclib plus everolimus in patients with high-grade glioma announced

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

New Columbia-Pfizer Clinical Trials Diversity Initiative aims to reduce health disparities

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

HIV vaccine candidate trialed in Sub-Saharan Africa falls short

Trial tests effectiveness of two prospective stroke therapies over standard of care

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

UniSA researchers are putting cancer patients at the heart of clinical trials

Investigational vaccine does not provide sufficient protection against HIV infection

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

NIH begins clinical trial to assess extra COVID-19 vaccine dose in people with autoimmune disease

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News